Neuro-Oncology 17:555565 Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, Dibble CC, DeNicola GM (2019) Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
In the STEP-1 clinical trial of semaglutide, roughly 45% of total weight lost was lean body mass rather than fat
The requirement for GLP-1 molecules has grown exponentially in recent years due to the rising prevalence of type 2 diabetes and obesity
LTB4R, leukotriene B4 receptor
Oxygen Radicals in Biological Systems
10.1016/S0024-3205(02)01637-5 [DOI] [PubMed] [Google Scholar] 46.Frerker N, Raber K, Bode F, Skripuletz T, Nave H, Klemann C, et al